GC Pharma says, ‘COVID-19 plasma treatment can be commercialized in second half’
GC Pharma says, ‘COVID-19 plasma treatment can be commercialized in second half’
  • Jung Jun-ho
  • 승인 2020.04.03 10:55
  • 댓글 0
이 기사를 공유합니다

GC Pharma announced on April 2 that the COVID-19 blood medicine "GC5131A," which the company is developing, will be commercialized in the second half of this year.

The GC5131A is a hyperimmune globulin made by dividing only immune proteins containing various antibodies in the plasma of COVID-19 recovery patients. The difference is that there are more antibodies specialized for COVID-19 than representative blood product Immune globulin, which consists of general immune antibodies.

The reason for the rapid development of plasma therapy is that it is an immune globulin drug that has been used in the human body for a long time.

Unlike the development of new drugs, the development process can be simplified because the working mechanisms and methods of production are the same as those of identical products already commercialized.

A company official said, "We have already seen the effects of treating new infectious diseases in the past by administering plasma to recovery patients, so the results of the drug's treatment are already out."

The world's top blood product companies, such as Takeda and Grifols, are developing COVID-19 blood plasma products like GC Pharma with support from governments. They are also reportedly aiming to commercialize the treatment within the year.

Huh Eun-chul, CEO of GC Pharma , said that the clinical trials for treatment will soon begin, adding that the treatment will be developed for the most urgent purpose of treating serious patients and protecting high-risk groups such as frontline medical staff.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.